Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

One FDA page now lists semaglutide as “in shortage,” while another says that all doses are available. The shortage of tirzepatide, the drug used in Mounjaro and Zepbound, is now marked ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Half of the patients took low doses of semaglutide, and half received placebo shots. The participants spent two hours in a lab room stocked with their preferred alcoholic beverages — once before ...

A study of 48 people with signs of moderate alcohol-use disorder found that those taking low doses of semaglutide ... Mounjaro for diabetes and Zepbound for obesity, based on the active ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

Now, according to US scientists, the injections — taken in small doses — could cut the amount people drank by almost half. Researchers couldn't be sure why the medicines, collectively known ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly sells the other major drugs in the class, Mounjaro for diabetes and Zepbound for obesity ... for women or five for men.Half received low-dose injections of semaglutide each week and ...